Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors
Cardiovascular disease (CVD) is the primary cause of death worldwide 1. The main risk factors for developing CVD are hyperlipidemia, high blood pressure, cigarette smoking and diabetes mellitus (DM) 2. The ESC guidelines have set distinct goals to prevent disease progression, following large clinical trials 3-5. The FOURIER study investigated the clinical benefit of LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD) and showed a 20% reduction of major adverse cardiovascular events (MACE) through an 59% LDL-C reduction 6.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: David Pinsdorf, Daniel Messiha, Olga Petrikhovich, Mikail Bahar, Martin Steinmetz, Amir Abbas Mahabadi, Iryna Dykun, Julia Lortz, Tienush Rassaf, Christos Rammos Tags: Original Research Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Hypertension | Lipidology | Smokers | Study